NATCO launches fixed dose combination of drug Sofosbuvir-Daclatasvir for Hepatitis C treatment in INDIA

Myequity news service | Date : 02-07-2018 14:30:00 IST

Natco Pharma Limited today announced that it is the first company to launch the fixed dose combination of Sofosbuvir-Daclatasvir tablets for the treatment of Hepatitis C under the brand name Hepcinat Plus, in India.

Hepcinat Plus is a generic fixed dose combination of Sofosbuvir 400 mg and Daclatasvir 60mg Tablet, for the treatment of patients with chronic hepatitis C virus (HCV) infection.

Natco pharma priced its generic medicine Hepcinat Plus, at Rs 17,500 for a bottle of 28 tablets, the company said.

About Natco Pharma Limited:

Natco Pharma Ltd was incorporated in Hyderabad in 1981 with an initial investment of about USD 54,954. With a modest beginning of operations as a single unit with 20 employees, NATCO today has five manufacturing facilities spread across India with dedicated modern research laboratories, capabilities in new drug development, etc.

NATCO is utilising its collective professional experience to kickstart its transformation into a major player in the global pharmaceutical industry. In addition, NATCO also exports its finished products to countries in North America, Europe, South America, Middle East and Southeast Asia.

Natco Pharma Limited closed 1.81% down at Rs 791.10


More from Myequity